Neurology Pharmacotherapy Review

Prescribing medications for neurological conditions is a cornerstone of clinical pharmacy, requiring a precise understanding of pathophysiology, drug mechanisms, and vigilant monitoring. As a future pharmacist, you must navigate complex treatment algorithms, manage chronic therapy, and prevent serious adverse events.

Antiepileptic Drugs: Selection Based on Seizure Type

Effective treatment of epilepsy begins with accurate seizure classification. Antiepileptic drugs (AEDs) work by modulating neuronal excitability, primarily through enhancing GABAergic inhibition, blocking voltage-gated sodium or calcium channels, or inhibiting excitatory glutamate transmission. Drug selection is dictated by the specific seizure type, as using a drug for the wrong classification can worsen seizures.

For focal-onset seizures (previously called partial seizures), first-line agents include levetiracetam, lamotrigine, and carbamazepine. In contrast, for generalized tonic-clonic seizures, valproic acid, lamotrigine, and levetiracetam are preferred. Absence seizures, a type of generalized seizure, are uniquely treated with ethosuximide or valproic acid; carbamazepine is contraindicated as it can exacerbate them. When initiating therapy, the principle is "start low, go slow" to improve tolerability. For refractory epilepsy, combination therapy is employed, often selecting agents with complementary mechanisms of action while carefully monitoring for additive side effects like sedation or dizziness.

Dopaminergic Agents and Parkinson Disease Management

Parkinson disease (PD) management aims to restore dopaminergic signaling in the nigrostriatal pathway. The cornerstone is levodopa, always administered with carbidopa, a peripheral dopa-decarboxylase inhibitor that reduces peripheral conversion to dopamine and minimizes side effects like nausea. While highly effective, long-term levodopa use is associated with motor complications such as dyskinesias and the "wearing-off" phenomenon.

The treatment algorithm is guided by patient age and symptom severity. For younger patients (typically <65 years), therapy often begins with a dopamine agonist (e.g., pramipexole, ropinirole) or an MAO-B inhibitor (e.g., rasagiline, selegiline) to delay levodopa introduction and its associated motor complications. For older patients or those with more significant functional impairment, levodopa/carbidopa is first-line due to its superior efficacy. COMT inhibitors like entacapone are used adjunctively with levodopa to prolong its effect by blocking its metabolism, helping to manage "off" periods.

Disease-Modifying Therapies for Multiple Sclerosis

Disease-modifying therapies (DMTs) for multiple sclerosis (MS) do not cure the disease but reduce the frequency and severity of relapses and slow the accumulation of disability. They are broadly categorized by their route of administration, mechanism, and efficacy.

First-line injectable therapies include interferon beta formulations and glatiramer acetate. Oral agents like fingolimod, dimethyl fumarate, and teriflunomide offer improved convenience and are often used after first-line failure or as initial therapy for more active disease. For highly active or rapidly progressing MS, high-efficacy monoclonal antibodies are employed. These include natalizumab (targets alpha-4 integrin, carries risk of PML), ocrelizumab (anti-CD20 for primary progressive and relapsing MS), and alemtuzumab (anti-CD52, with significant immune-related risks). Selection depends on disease activity, patient comorbidities, reproductive plans, and risk tolerance, requiring thorough patient counseling.

Pharmacotherapy for Migraine and Neuropathic Pain

Migraine treatment is stratified into acute (abortive) and preventive therapy. For acute treatment, triptans (e.g., sumatriptan) are first-line for moderate-to-severe migraines; they are serotonin 5-HT1B/1D receptor agonists that cause cranial vasoconstriction and inhibit neurogenic inflammation. For patients with cardiovascular contraindications to triptans, ditans (lasmiditan) or gepants (ubrogepant, rimegepant) are newer options that lack vasoconstrictive properties. Preventive therapy, for patients with frequent attacks, includes beta-blockers (propranolol), anticonvulsants (topiramate, valproate), tricyclic antidepressants (amitriptyline), and CGRP monoclonal antibodies (erenumab, fremanezumab).

Neuropathic pain treatment follows a different pathway. First-line pharmacotherapy includes gabapentinoids (gabapentin, pregabalin), serotonin-norepinephrine reuptake inhibitors (SNRIs) like duloxetine and venlafaxine, and tricyclic antidepressants (amitriptyline, nortriptyline). Topical agents (lidocaine, capsaicin) are useful for localized pain. Opioids are generally avoided due to high risk of misuse and limited long-term efficacy in neuropathic conditions.

Monitoring and Therapeutic Drug Monitoring

Vigilant monitoring is critical for safety and efficacy in neurology pharmacotherapy. For AEDs, baseline and periodic monitoring of complete blood count (CBC) and liver function tests (LFTs) is crucial for agents like carbamazepine and valproic acid. Therapeutic drug monitoring (TDM) is especially valuable for drugs with a narrow therapeutic index, such as phenytoin, carbamazepine, and valproic acid. TDM helps individualize dosing, assess compliance, diagnose toxicity, and adjust for drug interactions or altered physiology (e.g., pregnancy, aging).

For Parkinson's medications, monitor for motor complications (dyskinesias, "off" periods), neuropsychiatric effects (hallucinations with dopamine agonists), and impulse control disorders. With MS DMTs, monitoring varies by agent but can include regular CBC/LFTs, MRI for disease activity, and specific screenings (e.g., JC virus antibody for natalizumab, thyroid function for alemtuzumab). For migraine and neuropathic pain drugs, assess for treatment response, sedation (with gabapentinoids or TCAs), and anticholinergic side effects.

Common Pitfalls

Mismatching AEDs to Seizure Type: A classic exam trap is selecting carbamazepine for absence seizures or juvenile myoclonic epilepsy, which it can worsen. Always verify the seizure classification before recommending an AED. Correct approach: Use ethosuximide or valproic acid for absence seizures.

Ignoring Drug Interaction Risks with Levodopa: Levodopa's absorption is impaired by high-protein meals and its effects can be antagonized by typical antipsychotics. Furthermore, non-selective MAO inhibitors are contraindicated due to hypertensive crisis risk. Correct approach: Counsel patients to take levodopa 30-60 minutes before meals and verify all concomitant medications for interactions.

Overlooking Required Monitoring for DMTs: Prescribing a high-efficacy MS therapy like natalizumab without checking JC virus antibody status or monitoring lymphocytes with fingolimod creates significant patient risk. Correct approach: Adhere strictly to the risk evaluation and mitigation strategies (REMS) and monitoring protocols for each DMT.

Using Inappropriate Agents for Neuropathic Pain: Initiating therapy with an opioid or a non-steroidal anti-inflammatory drug (NSAID) for diabetic neuropathy is ineffective and unsafe. Correct approach: Start with a guideline-recommended first-line agent like gabapentin, pregabalin, duloxetine, or amitriptyline.

Summary

• Drug selection in epilepsy is specific to seizure type. Focal seizures and generalized tonic-clonic seizures have different first-line agents, and misuse (e.g., carbamazepine for absence seizures) can exacerbate the condition.
• Parkinson disease management follows an age- and symptom-driven algorithm. Younger patients often start with dopamine agonists to delay levodopa complications, while levodopa remains the most effective symptomatic therapy.
• Multiple sclerosis DMTs range from moderate-efficacy injectables to high-efficacy infusions. Choice is based on disease activity, safety profile, and patient-specific factors, with stringent monitoring requirements.
• Migraine therapy is stratified into acute (triptans, gepants) and preventive (beta-blockers, anti-CGRP) treatments. Neuropathic pain is distinct and is treated first-line with gabapentinoids, SNRIs, or TCAs.
• Therapeutic drug monitoring and adverse effect surveillance are non-negotiable for antiepileptic drugs, immunomodulators, and dopaminergic agents to ensure safety and optimize therapeutic outcomes.